Consolidation and Maintenance therapy
|
|
- Shanon Fisher
- 5 years ago
- Views:
Transcription
1 University of Salamanca Consolidation and Maintenance therapy María-Victoria Mateos, MD, PhD University Hospital of Salamanca, Spain
2 Disclosure form MVM has served as member of advisory boards or received honoraria from lectures for Takeda, Celgene, Janssen, BMS, Amgen.
3 Definition and Aims of consolidation and maintenance therapy Consolidation Improve response/induce deeper response following therapy by administration of treatment for a limited period Maintenance Maintain response achieved following therapy by administration of treatment for a prolonged period Overall goal: Improve the quality of response Sustain MRD-/+ Extend progression free survival Prolong survival
4 The true value of CR relies on the MRD status, and CR w/o MRD is no better than PR MRD-negative vs CR: p < CR vs ncr: p = MRD-negative vs CR: p < CR vs ncr: p = Progression-free survival (%) Overall survival (%) p < p < Time from response assessment (months) Time from response assessment (months) MRD-negative (n = 316) median PFS: 58 months CR (n = 128) median PFS: 24 months ncr (n = 96) median PFS: 21 months PR (n = 199) median PFS: 26 months MRD-positive < PR (n = 38) median PFS: 9 months MRD-negative (n = 316) median OS: 145 months CR (n = 128) median OS: 59 months ncr (n = 96) median OS: 63 months PR (n = 199) median OS: 59 months < PR (n = 38) median OS: 32 months GEM2000, GEM2005MENOS65, GEM2005MAS65, GEM2010MAS65 (n = 777) ncr, near complete response;; OS, overall survival;; PFS, progression-free survival;; PR, partial response. Lahuerta JJ, et al. manuscript under review.
5 All levels of MRD are usually associated with unsustained remissions Next-generation flow 1 Next-generation sequencing 2 Progression-free survival (%) NGF-negative (n = 37), 75% PFS: NR* NGF-positive/2 nd gen-positive (n = 26), 75% PFS: 12 months NGF-positive/2 nd gen-negative (n = 16), 75% PFS: 10 months p = 0.04 Patients without progression (%) MRD at post-maintenance p value (trend) < <10-6 [10-6 ;; 10-5 ] [10-5 ;; 10-4 ] ³ Time from MRD assessment (months) Months since randomization Heterogeneous patient population (not enrolled in clinical trials) NGF, next-generation flow. IFM 2009 trial: patients who received either 8 cycles of VRD (arm A) or 3 VRD cycles, high-dose melphalan, followed by 2 consolidation VRD cycles (arm B). All patients received a lenalidomide maintenance dose for 12 months. 1. Flores-Montero J, et al. manuscript under review. 2. Avet-Loiseau H, et al. Blood. 2015;;126:abstract 191. As presented at ASH 2015.
6 Undetectable MRD can be associated with operational cure Total number of tumour cells Presentation PR VGPR CR scr MRD Undetectable MRD - (Operational cure) - Diagnosis End of therapy Time to progression Rationale for maintenance would be based on the continuous control of MRD, negative or even positive CR, complete response;; MRD, minimal residual disease;; PR, partial response;; scr, stringent CR;; VGPR, very good PR. Mateos MV, et al. Blood Rev. 2015;;29:
7 Long-term survival is possible for a few MRD-positive patients with a unique immune profile Dcs, dendritic cells;; MO, monocyte;; NK, natural killer;; TAMs, tumour associated macrophages;; T-Reg, T-regulatory cell. Pessoa de Magalhães RJ, et al. Haematologica. 2013;;98: As presented at ASH 2011.
8 Prognostic value of immune reconstitution in patients with persistent MRD Single 8-colour combination (CD45, CD138, CD38, CD56, CD27, CD19, CD117, CD81): enumeration of 15 different BM cell populations MRD-positive MRD-positive high normal PC recovery and favourable immune profile MRD-negative B-precursors Erythroblasts PCA3 Individual patients immune signatures Time to progression (%) p = Median TTP: NR Median TTP: NR Median TTP: 16 m PCA1 Clonal PCs Normal PCs Time from MRD assessment (months) 50 Patients with favourable immune profile are characterized by an increased compartment of mature B cells BM, bone marrow;; PCA, principal component analysis;; PCs, plasma cells. Paiva B, et al. Blood. 2016;;127: As presented at ASH 2015.
9 Transplant Candidate: Consolidation/Maintenance What are the options? Consolidation High-dose chemotherapy + transplant, single or tandem Regimens based on Bortezomib Thalidomide Lenalidomide Maintenance Interferon-alpha Steroids Thalidomide Bortezomib Lenalidomide
10 IFM 2009: PFS and OS RVD arm vs Transplant arm CR: 49% 59% VGPR: 78% 88% PFS OS HDT no HDT Patients (%) P<0.001 Patients (%) P NS Months of follow-up N at risk HDT no HDT Months of follow-up N at risk HDT no HDT HDT no HDT Attal M. ASH 2015
11 EMN02/HO95 MM trial: study design (n = 1192) VMP arm vs Transplant arm after VCD x 3 cycles CR: 43% 42% VGPR: 73% 85% Progression-free survival (%) 1,00 0,50 0,00 Number at risk ASCT VMP PFS ASCT Time (months) ASCT VMP PFS median, mos NR 44 PFS at 3 yrs, % HR (95% CI): 0.73 ( );; p = Superior PFS with ASCT vs VMP was retained across prespecified subgroups of patients at low (NR vs 46m) and high risk (42 vs 32m) Cavo M. ASCO 2015 VMP
12 Double ASCT after bortezomib-based induction as consolidation therapy PFS and OS in patients with 2 adverse variables Double ASCT Single ASCT P PFS 41 months 20 months OS 67 months 31.5 months <0.001 PFS and OS for pts with high-risk cytogenetics and who failed CR after bortezomib-based induction regimens PFS OS Cavo M et al. Blood 2013;;122:767.
13 Consolidation Therapy Induction Regimen Response Post- Induction Response Post- ASCT Response Post- Consolidation CR (%) CR (%) CR (%) VTD RVD KTD KRd Consolidation upgraded response in approximately 30%. 1. Cavo M et al. Blood. 2012;; 120:9. 2. Roussel M et al. Blood. 2011;;118: Abstract Sonneveld P et al. Blood. 2015;;125: Zimmerman TM et al. J Clin Oncol. 2015;;33. Abstract 8510.
14 Phase III BMT CTN 0702 Trial: SCHEMA - Lenalidomide maintenance* Register and randomize ASCT MEL 200 mg/m 2 RVD 4* Lenalidomide maintenance *Bortezomib 1.3 mg /m 2 days 1, 4, 8, 11 Lenalidomide 15 mg days 1 15 Dexamethasone 40 mg days 1, 8, 15 Lenalidomide 15 mg daily 3 years ASCT MEL 200 mg/m 2 Lenalidomide maintenance
15 Transplant Candidate: Consolidation/Maintenance What are the options? Consolidation High-dose chemotherapy ± transplant, single or tandem Regimens based on Bortezomib Thalidomide Lenalidomide Maintenance Interferon-alpha Steroids Thalidomide Bortezomib Lenalidomide
16 Thalidomide maintenance studies Significant improvement in PFS with maintenance therapy Significant improvement in OS with maintenance therapy Survival after relapse Spencer 2009 Yes Yes (3-year follow-up) Similar in all groups Attal 2006 Yes Yes (at 39 months), but OS advantage disappeared with longer follow-up (5.7 years) Similar in all groups Barlogie 2006, 2008, 2010 Yes Yes (7.2-year follow-up) Reduced OS after thalidomide exposure Lokhorst 2010 Yes No Reduced OS after thalidomide exposure Morgan 2012 Yes No Reduced OS after thalidomide exposure Stewart 2013 Yes No Reduced OS after thalidomide exposure Toxicity, particularly neurological, leads to discontinuation rates up to 60%, and worse QoL Worse OS in patients with adverse FISH This table is provided for ease of viewing information from multiple trials. Direct comparisons across trials is not intended and should not be inferred. FISH, in situ fluorescence hybridization;; QoL, quality of life. Attal M, et al. Blood. 2006;;108: Barlogie B, et al. N Engl J Med. 2006;;354: Barlogie B, et al. Blood. 2008;;112: Barlogie B, et al. J Clin Oncol. 2010;;28: Lokhorst HM, et al. Blood. 2010;;115: Morgan GJ, et al. Blood. 2012;;119:7-15. Spencer A, et al. J Clin Oncol. 2009;;27: Stewart AK, et al. Blood. 2013;;121:
17 Studies included in meta-analysis (N = 1,209) CALGB (accrual 8/ /2009) IFM (accrual 6/2006 8/2008) GIMEMA (RV-MM-PI-209) (accrual 11/2007 7/2009) INDUCTION ASCT 1:1 RANDOMIZATION NO EVIDENCE OF PD INDUCTION ASCT 1:1 RANDOMIZATION NO EVIDENCE OF PD ASCT 2 2 DESIGN LEN + DEX 4 INDUCTION MPR: 6 COURSES LEN: 2 COURSES PLACEBO (n = 229) LEN MNTC a (n = 231) PLACEBO (n = 307) LEN MNTC a (n = 307) NO TREATMENT (n = 68) LEN MNTC b (n = 67) NO TREATMENT LEN MNTC b INTERIM ANALYSIS INTERIM AND ANALYSIS AND UNBLINDING UNBLINDING Dec 2009 Dec 2009 Jan 2010 CROSSOVER BEFORE PD ALLOWED CONTINUED TREATMENT NO CROSSOVER BEFORE PD ALLOWED CONTINUED TREATMENT ALL TREATMENT DISCONTINUED Jan 2011 PRIMARY ANALYSIS CONTINUED TREATMENT CONTINUED TREATMENT Target population of patients with NDMM who received LEN maintenance or placebo/no maintenance after ASCT a Starting dose of 10 mg/day on days 1 28/28 was increased to 15 mg/day if tolerated and continued until PD. b Patients received 10 mg/day on days 1 21/28 until PD. The PFS in the LEN arm was doubled vs placebo arms (41-46 months vs months) in all studies DEX, dexamethasone;; LEN, lenalidomide;; MNTC, maintenance;; NDMM, newly diagnosed multiple myeloma;; PD, progressive disease. Attal M, et al. J Clin Oncol. 2016;;34 Suppl:abstract 8001.
18 Lenalidomide maintenance: OS meta-analysis 26% reduction in risk of death, representing an estimated 2.5-year increase in median survival a year OS Median follow-up: 80 months Survival probability N = 1,209 N = 1209 LEN CONTROL Median OS (95% CI), months NE (NE NE) 86.0 ( ) 50% 62% 0 Patients at risk HR (95% CI) p value 0.74 ( ) Overall survival (months) The OS benefit was observed in all investigated subgroups of patients (except high-risk CA and ISS stage III) LEN maintenance after ASCT can be considered a standard of care a Median for LEN treatment arm was extrapolated to be 116 months based on median of the control arm and HR (median 86 months;; HR = 0.74). Attal M, et al. J Clin Oncol. 2016;;34 Suppl:abstract CA, cytogenetic abnormality;; ISS, International Staging System;; NE, not estimable.
19 Bortezomib maintenance therapy Study details n Treatment Outcome PFS OS HOVON 65 MM/ GMMG-HD PAD x 3 à HDM à bortezomib every 2 weeks for 2 years 34 months 90 Median follow-up: 91 months 414 VAD x 3 à HDM à thalidomide daily for 2 years 28 months p = months RMS 8y (4.8 months) p = 0.04 PETHEMA/GEM 2 Median follow-up: 34.9 months VT (1 cycle bortezomib every 3 months, thalidomide daily) for 3 years Thalidomide (daily for 3 years) Significant PFS benefit for VT p < OS not significantly different between arms 90 Interferon-a 2b (3 x per week for 3 years) HOVON 65 MM PAD x3 tandem HDM bortezomib maintenance: benefit for patients with del(17p) Bortezomib maintenance after double ASCT is effective in patients with del(17p) Bortezomib administered at 1.3 mg/m 2 i.v. in both studies HDM, high-dose melphalan;; i.v., intravenous;; PAD, bortezomib, doxorubicin, dexamethasone;; RMS 8y, restricted mean survival time at 8 years;; VAD, vincristine, doxorubicin, dexamethasone. 1. Sonneveld P, et al. Blood. 2015;;126:abstract 27. Presented at ASH Rosinol L, et al. Blood. 2012;;120:334. Presented at ASH 2012.
20 Ixazomib: oral proteasome inhibitor Best response to treatment in phase 2 patients receiving maintenance with ixazomib after IRd as induction (N = 21) 100% 90% 80% 5 19 n = 2 n = % 60% 50% 40% 30% 48 n = 5 n = scr CR ncr VGPR PR 20% 10% % Best response to induction Best response overall 10 (48%) patients improved their response during maintenance 2 VGPR to ncr, 5 VGPR to CR, 1 VGPR to scr, and 2 CR to scr Ixazomib maintenance promising but data from phase 3 trial are pending IRd, ixazomib, lenalidomide, dexamethasone;; ncr, near partial response. Kumar S, et al. Lancet Oncol (13):
21 Non-Transplant Candidate: Consolidation/Maintenance What are the options? Consolidation Maintenance Thalidomide No trials Bortezomib Lenalidomide
22 GEM2016FIT: Consolidation (R1) Induction 18 cycles Consolidation (R2) Maintenance NDMM patients NS CTC >65 y n= 462 elderly Fit Patients (GHA) ARM 1 VMP N=154 Mel: 9mg/m 2 D1-4 Pred: 60mg/m 2 D1-4 BTZ: 1.3mg/m 2 D1, 8,15,22 ª One 6 week cycle followed by eight 4-week cycle N=159 ARM 2a KRd.N=154 CFZ: 20/70 mg/m 2, d1, 8, 15 LEN: 25 mg, d1 21 DEX: 20/10 mg, d1, 2, 8, 9, 15, 16, 22, day cycles N=159 ARM 2b KRD- DARA n=154 Rd LEN: 25 mg, d1 21 DEX: 20/10 mg, d1, 2, 8, 9, 15, 16, 22, 23 Nine 28-day cycles CFZ: 20/70 mg/m 2, d1, 8, 15 LEN: 25 mg, d1 21 DEX: 20/10 mg, d1, 2, 8, 9, 15, 16, 22, 23 Dara 16 mg/kg IV Days 1, 8, 15, 22 of cycles 1-2; Days 1 and 15 of cycles 3 and 4; Day 1 of cycles 5 to 18 Rd LEN: 25 mg, d1 21 DEX: 20/10 mg, d1, 2, 8, 9, 15, 16, 22, 23 Dara 16 mg/kg Days 1, 8, 15, 22 of cycles 1-2; Days 1 and 15 of cycles 3 and 4 Four 28-day cycles Directly to the R2 maintenance fase MRD+ MRD- No maintenance Dara 16 mg/kg IV Day 1 of cycles R 15 mg, d1 21 Until progresion No maintenance Dara 16 mg/kg IV Day 1 of cycles R 15 mg, d1 21 Until progresion * * MRD 9 cy MRD 18 cy MRD 22 cy Primary endpoint immonuphenotipic complete response Secondary exploratory outcome: PFS * Patientes in Biological relapse will be rechallenge by Dra + R a During the first cycle (6 weeks), bortezomib is given on D1, 4, 8, 11, 22, 25, 29, and 32.; GAH: J Geriatr Oncol Sep;;6(5):353-61;; R1: first randomization;; R2: second randomization ;; IMF imnunofenotipicresponse NGF ( next generation flow) 2
23 FIRST trial: lenalidomide as continuous therapy Rd until DP vs Rd for 18 cycles vs MPT x 18 cycles, N = 1,623 patients 100 PFS Median PFS 100 OS 4-year OS Rd (n = 535) 59.4% 80 Rd (n = 535) Rd18 (n = 541) MPT (n = 547) 25.5 m 20.7 m 21.2 m 80 Rd18 (n = 541) 55.7% MPT (n = 547) 51.4% Patients (%) 60 Patients (%) HR Rd vs MPT: 0.72;; p = Rd vs Rd18: 0.70;; p = Rd18 vs MPT: 1.03;; p = Months 20 0 HR Rd vs MPT: 0.78;; p = (È 22% risk of death with Rd) Rd vs Rd18: 0.90;; p = Rd18 vs MPT: 0.88;; p = Months Continuous Rd reduced the risk of DP and death by 28% and 22% vs MPT, respectively. Rd as continuous therapy is a standard of care DP, disease progression;; m, months;; MPT, melphalan, prednisolone, thalidomide;; Rd18, lenalidomide and low-dose dexametasone for 18 cycles. Facon T, et al. N Engl J Med. 2014;;371:
24 Bortezomib as maintenance: VMPT VT x 2 y vs VMP with no maintenance (GIMEMA-MM-03-05;; N = 511) VMPT VMPT Progression-free survival Landmark analysis VT maintenance Maintenance Off therapy VMPT Overall Overall Survival survival (OS) 30% reduced risk of death 30% Reduced Risk of Death VT maintenance Maintenance Off therapy years PFS Median PFS years OS Median OS VMPT-VT 33% 31.5 months VMPT-VT 61% Not reached 0.75 VMP 16% 17.8 months 0.75 VMP 51% 60.6 months Patients (%) 0.50 Patients (%) Time (months) 0.00 HR 0.70, HR 95% 0.70, CI 95% , CI, , p = 0.01 P = Time (months) Time to next therapy: 46.6 vs 27.8 months and OS from relapse identical Bortezomib as maintenance is feasible during a fixed time y, years. Palumbo A, et al. J Clin Oncol. 2014;;32:
25 Summary (I) Maintenance therapy seems to benefit patients with MM after ASCT and as continuous therapy in non-asct candidates. However,... Some questions remain open: What is the optimal duration of maintenance? Can we personalize the maintenance?
26 Maintenance therapy after ASCT: future Sponsor/cooperative group IFM/DFCI 2009 Myeloma XI GEM14MAIN GMMHD6 GIMEMA SWOG US Cooperative group trials (pick the winner) ECOG-ACRIN study AFT-40 C16019 HOVON-IFM CCT-PNK-004-mmy001 Treatment Lenalidomide-based Lenalidomide x 1 year vs lenalidomide until DP Lenalidomide vs lenalidomide + vorinostat vs no maintenance Lenalidomide vs lenalidomide + ixazomib for up to 2 years Patients with MRD will continue 3 additional years Lenalidomide-dexamethasone vs lenalidomide-dexamethasone + elotuzumab Lenalidomide vs lenalidomide + carfilzomib Lenalidomide vs lenalidomide + ixazomib until DP Lenalidomide vs lenalidomide + vaccination/lenalidomide x 2 years vs lenalidomide until DP Lenalidomide vs lenalidomide + ixazomib Lenalidomide x 2 years vs lenalidomide until DP Lenalidomide vs lenalidomide + durvalumab vs lenalidomide + daratumumab vs lenalidomide + ACY-241 Other Ixazomib for up to 2 years vs placebo Daratumumab vs placebo Human cord blood derived, cultured and expanded NK cells NK, natural killer.
27 Maintenance therapy in transplant-ineligible patients Transplant-ineligible patients benefit from CT until DP Some studies are investigating maintenance therapy Sponsor/cooperative group Treatment C16019 Takeda Millennium Ixazomib for up to 2 years vs placebo Myeloma XI Future new standards of care LEN vs LEN + vorinostat vs no maintenance LEN-DEX + daratumumab until DP LEN-DEX + elotuzumab until DP LEN-DEX + ixazomib until DP LEN-DEX + carfilzomib LEN-DEX + bortezomib followed by LEN-DEX
28 Will it be possible to personalize maintenance? Personalization of maintenance type: standard risk versus high risk, based on cytogenetic abnormalities, ISS, LDH, etc. - Single agent for standard risk patients, len or ixa? - PI & IMiDs for high risk or just PI? toxicity during maintenance, QoL Personalization of maintenance duration response status at start of maintenance: MRD-negative versus MRD-positive MRD status during maintenance biomarkers: which maintenance drug or drug combination will my individual patient benefit most from? MRD only at the Bone Marrow level, or combine MRD by NGS/NGF with PET-CT?? ISS, International Staging System;; LDH, lactate dehydrogenase;; MRD, minimal residual disease;; QoL, quality of life.
29 PETHEMA GEM 2014 study European trial investigating different durations of maintenance MRD negative: 2 years MRD positive: up to 5 years GEM2012MENOS65 n = 316 R Len + dex Len + dex + Ixazomib MRD evaluation at 2 years MRD negative MRD positive End of treatment Len + dex up to 3 years PFS Annual MRD dex, dexamethasone;; Len, lenalidomide;; R, randomization. NCT at
30 GEM2016FIT: Consolidation (R1) Induction 18 cycles Consolidation (R2) Maintenance NDMM patients NS CTC >65 y n= 462 elderly Fit Patients (GHA) ARM 1 VMP N=154 Mel: 9mg/m 2 D1-4 Pred: 60mg/m 2 D1-4 BTZ: 1.3mg/m 2 D1, 8,15,22 ª One 6 week cycle followed by eight 4-week cycle N=159 ARM 2a KRd.N=154 CFZ: 20/70 mg/m 2, d1, 8, 15 LEN: 25 mg, d1 21 DEX: 20/10 mg, d1, 2, 8, 9, 15, 16, 22, day cycles N=159 ARM 2b KRD- DARA n=154 Rd LEN: 25 mg, d1 21 DEX: 20/10 mg, d1, 2, 8, 9, 15, 16, 22, 23 Nine 28-day cycles CFZ: 20/70 mg/m 2, d1, 8, 15 LEN: 25 mg, d1 21 DEX: 20/10 mg, d1, 2, 8, 9, 15, 16, 22, 23 Dara 16 mg/kg IV Days 1, 8, 15, 22 of cycles 1-2; Days 1 and 15 of cycles 3 and 4; Day 1 of cycles 5 to 18 Rd LEN: 25 mg, d1 21 DEX: 20/10 mg, d1, 2, 8, 9, 15, 16, 22, 23 Dara 16 mg/kg Days 1, 8, 15, 22 of cycles 1-2; Days 1 and 15 of cycles 3 and 4 Four 28-day cycles Directly to the R2 maintenance fase MRD+ MRD- No maintenance Dara 16 mg/kg IV Day 1 of cycles R 15 mg, d1 21 Until progresion No maintenance Dara 16 mg/kg IV Day 1 of cycles R 15 mg, d1 21 Until progresion * * MRD 9 cy MRD 18 cy MRD 22 cy Primary endpoint immonuphenotipic complete response Secondary exploratory outcome: PFS * Patientes in Biological relapse will be rechallenge by Dra + R a During the first cycle (6 weeks), bortezomib is given on D1, 4, 8, 11, 22, 25, 29, and 32.; GAH: J Geriatr Oncol Sep;;6(5):353-61;; R1: first randomization;; R2: second randomization ;; IMF imnunofenotipicresponse NGF ( next generation flow) 2
31 Summary Maintenance therapy seems to benefit patients with MM after ASCT and as continuous therapy in non- ASCT candidates. Understanding the role of MRD and immune reconstitution should allow us to further improve the optimal maintenance therapy, duration, to prolong OS Developing early endpoints as surrogate markers for long-term outcomes and OS is critically important;; otherwise, trials may continue for 10 years or longer
Role of consolidation therapy in Multiple Myeloma. Pieter Sonneveld. Erasmus MC Cancer Institute Rotterdam The Netherlands
Role of consolidation therapy in Multiple Myeloma Pieter Sonneveld Erasmus MC Cancer Institute Rotterdam The Netherlands Disclosures Research support : Amgen, Celgene, Janssen, Karyopharm Advisory Boards/Honoraria:
More informationInitial Therapy For Transplant-Eligible Patients With Multiple Myeloma. Michele Cavo, MD University of Bologna Bologna, Italy
Initial Therapy For Transplant-Eligible Patients With Multiple Myeloma Michele Cavo, MD University of Bologna Bologna, Italy Treatment Paradigm for Autotransplant-Eligible Patients With Multiple Myeloma
More informationCOMy Congress The case for IMids. Xavier Leleu. Hôpital la Milétrie, PRC, CHU, Poitiers, France
Xavier Leleu Hôpital la Milétrie, PRC, CHU, Poitiers, France The case for IMids COMy Congress 21 Disclosures Grants/research support: Amgen, Bristol-Myers Squibb, Celgene, Janssen, Millennium/Takeda, Novartis,
More informationTreatment Advances in Multiple Myeloma: Expert Perspectives on Translating Clinical Data to Practice
Treatment Advances in Multiple Myeloma: Expert Perspectives on Translating Clinical Data to Practice Friday, December 2, 2016 San Diego, California This program is supported by educational grants from
More informationInduction Therapy in Transplant Eligible MM 2 December Tontanai Numbenjapon, M.D.
Induction Therapy in Transplant Eligible MM 2 December 2017 Tontanai Numbenjapon, M.D. What we need from induction therapy in NDMM Depth of response: MRD-negative, scr, CR Longest response Acceptable toxicity
More informationTo Maintain or Not to Maintain? Immunomodulators vs PIs Yes: Proteasome Inhibitors
To Maintain or Not to Maintain? Immunomodulators vs PIs Yes: Proteasome Inhibitors James Berenson, MD Institute for Myeloma and Bone Cancer Research West Hollywood, CA Financial Disclosures Takeda, Celgene
More informationDisclosures for Palumbo Antonio, MD
Disclosures for Palumbo Antonio, MD Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Honoraria Scientific Advisory Board o relevant conflicts of interest to declare o relevant
More informationContinuous Therapy as a Standard of Care CON. JL Harousseau Institut de Cancérologie de l Ouest Nantes Saint Herblain France
Continuous Therapy as a Standard of Care CON JL Harousseau Institut de Cancérologie de l Ouest Nantes Saint Herblain France 1 In France and in the IFM all debates 2 In France and in the IFM all debates
More informationUpdate on Multiple Myeloma Treatment
Update on Multiple Myeloma Treatment Professor Chng Wee Joo Director National University Cancer Institute of Singapore (NCIS) National University Health System (NUHS) Deputy Director Cancer Science Institute,
More informationMultiple myeloma, 25 (45) years of progress. The IFM experience in patients treated with frontline ASCT. Philippe Moreau, Nantes
Multiple myeloma, 25 (45) years of progress The IFM experience in patients treated with frontline ASCT Philippe Moreau, Nantes Shibata T. Prolonged survival in a case of multiple myeloma treated with high
More informationConsolidation and maintenance therapy for transplant eligible myeloma patients
Consolidation and maintenance therapy for transplant eligible myeloma patients Teeraya Puavilai, M.D. Division of Hematology, Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University
More informationStandard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant
Standard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant Pr Philippe Moreau University Hospital, Nantes, France MP: Standard of care until 2007 J Clin Oncol
More informationMULTIPLE MYELOMA. TREATMENT in 2017 MC. VEKEMANS
MULTIPLE MYELOMA TREATMENT in 2017 MC. VEKEMANS NATURAL HISTORY of MM WHO SHOULD BE TREATED? DEFINITION MGUS Smouldering Multiple Myeloma Symptomatic Multiple Myeloma Monoclonal component (blood and/or
More informationIs autologous stem cell transplant the best consolidation after initial therapy?
Is autologous stem cell transplant the best consolidation after initial therapy? William Bensinger, MD Professor of Medicine, Division of Oncology University of Washington School of Medicine Director,
More informationHow I Treat Transplant Eligible Myeloma Patients
How I Treat Transplant Eligible Myeloma Patients Michele Cavo Seràgnoli Institute of Hematology, Bologna University School of Medicine, Italy Podcetrtek, Slovene, April 14 th, 2012 NEW TREATMENT PARADIGM
More informationManaging Newly Diagnosed Multiple Myeloma
Managing Newly Diagnosed Multiple Myeloma 26 Jan 2018 Alfred Garfall, MD Assistant Professor of Medicine Diagnosis of Multiple Myeloma Traditional criteria: Monoclonal plasma cells + attributable CRAB
More informationTerapia del mieloma. La terapia di prima linea nel paziente giovane. Elena Zamagni
Terapia del mieloma La terapia di prima linea nel paziente giovane Elena Zamagni Istituto di Ematologia ed Oncologia Medica Seràgnoli Università degli Studi di Bologna Newly diagnosed MM Candidate for
More informationTREATMENT FOR NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA
TREATMENT FOR NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA Ekarat Rattarittamrong, MD Division of Hematology Department of Internal Medicine Faculty of Medicine Chiang Mai University OUTLINE Overview of treatment
More informationUnmet Medical Needs and Latest Multiple Myeloma Treatment
Unmet Medical Needs and Latest Multiple Myeloma Treatment Professor Chng Wee Joo Director National University Cancer Institute of Singapore (NCIS) National University Health System (NUHS) Deputy Director
More informationAutologous Stem Cell Transplantation in Multiple Myeloma Optimal Frontline Therapy and Maintenance Therapy
Autologous Stem Cell Transplantation in Multiple Myeloma Optimal Frontline Therapy and Maintenance Therapy Donna E. Reece, M.D. Princess Margaret Hospital Toronto, ON CANADA 10 December 2011 ASCT in Myeloma..
More informationCuring Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham
Curing Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham What is cure after all? Getting rid of it? Stopping treatment without
More informationChristine Chen Princess Margaret Cancer Centre September 2013
Christine Chen Princess Margaret Cancer Centre September 2013 Disclosures Research Support Celgene, Janssen, GSK Employee N/A Consultant N/A Major Stockholder Speakers Bureau/ Scientific Advisory Board
More informationVI. Autologous stem cell transplantation and maintenance therapy
Hematological Oncology Hematol Oncol 2013; 31 (Suppl. 1): 42 46 Published online in Wiley Online Library (wileyonlinelibrary.com).2066 Supplement Article VI. Autologous stem cell transplantation and maintenance
More informationMeu paciente realizou um TACTH na 1a linha, e agora? Tandem, Manutenção, Consolidação? Marcelo C Pasquini, MD, MS Medical College of Wisconsin
Meu paciente realizou um TACTH na 1a linha, e agora? Tandem, Manutenção, Consolidação? Marcelo C Pasquini, MD, MS Medical College of Wisconsin Post Auto HCT Options for MM Maintenance Lenalidomide vs.
More informationCOMy Congress A New Era of Advances in Myeloma. S. Vincent Rajkumar Professor of Medicine Mayo Clinic
A New Era of Advances in Myeloma S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of Medicine Mayo Clinic Comprehensive
More informationCME Information LEARNING OBJECTIVES
CME Information LEARNING OBJECTIVES Identify patients with MM who have undergone autologous stem cell transplant and would benefit from maintenance lenalidomide. Counsel older patients (age 65 or older)
More informationClinical Case Study Discussion: Maintenance in MM
www.comtecmed.com/comy comy@comtecmed.com Evangelos Terpos, MD, PhD National & Kapodistrian University of Athens, School of Medicine, Athens, Greece Clinical Case Study Discussion: Maintenance in MM Disclosure
More informationNovel Combination Therapies for Untreated Multiple Myeloma
Novel Combination Therapies for Untreated Multiple Myeloma Andrzej J. Jakubowiak, MD, PhD Director, Myeloma Program New York, NY, October 27, 201 Disclosures 2 Employee Consultant Major Stockholder Speakers
More informationMaintenance therapy after autologous transplantation
Maintenance therapy after autologous transplantation Sonja Zweegman MD PhD Department of Hematology Amsterdam The Netherlands Disclosures Research funding from Celgene, Takeda and Janssen Participation
More informationTiming of Transplant for Multiple Myeloma
Timing of Transplant for Multiple Myeloma Wenming CHEN Beijing Chaoyang Hospital Capital Medical University Multiple myeloma resrarch center of Beijing Initial Approach to Treatment of Myeloma Nontransplantation
More informationMYELOMA MAINTENANCE BEST PRACTICES:
MYELOMA MAINTENANCE BEST PRACTICES: POST THERAPY & POST TRANSPLANT Aric Hall, MD Assistant Professor University of Wisconsin Hospital and Clinics INTRODUCTION MYELOMA Clonal plasma cell malignancy leading
More informationInduction Therapy: Have a Plan. Sagar Lonial, MD Professor, Winship Cancer Institute Director of Translational Research, B-cell Malignancy Program
Induction Therapy: Have a Plan Sagar Lonial, MD Professor, Winship Cancer Institute Director of Translational Research, B-cell Malignancy Program Topics When to treat? Smoldering vs Symptomatic Risk stratification
More informationUK MRA Myeloma XII Relapsed Intensive Study CI: Prof Gordon Cook
UK Myeloma Research Alliance Myeloma XII study (ACCoRD): Augmented Conditioning & Consolidation in Relapsed Disease UK MRA Myeloma XII Relapsed Intensive Study CI: Prof Gordon Cook Sponsor ID: Pending
More informationHighlights from EHA Mieloma Multiplo
Highlights from EHA Mieloma Multiplo Michele Cavo Istituto di Ematologia L. e A. Seràgnoli Alma Mater Studiorum Università degli studi di Bologna Firenze, 22-23 Settembre 27 Myeloma XI TE pathway 7 R :
More informationProgress in Multiple Myeloma
Progress in Multiple Myeloma Sundar Jagannath, MD Professor, New York Medical College Adjunct Professor, New York University St. Vincent s Comprehensive Cancer Center, NY Faculty Disclosure Advisory Board:
More informationMultiple Myeloma: Induction, Consolidation and Maintenance Therapy
Multiple Myeloma: Induction, Consolidation and Maintenance Therapy James R. Berenson, MD Medical & Scientific Director Institute for Myeloma & Bone Cancer Research Los Angeles, CA Establish the Goals of
More informationNew IMWG Response Criteria
New IMWG Response Criteria Shaji Kumar, M.D. Professor of Medicine Division of Hematology Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of Medicine Mayo
More informationRole of Maintenance and Consolidation Therapy in Multiple Myeloma: A Patient-centered Approach
Role of Maintenance and Consolidation Therapy in Multiple Myeloma: A Patient-centered Approach Jacob Laubach, MD Assistant Professor in Medicine Harvard Medical School Clinical Director of the Jerome Lipper
More informationTreatment of elderly multiple myeloma patients
SAMO Interdisciplinary Workshop on Myeloma March 30 th -31 st 2012, Seehotel Hermitage, Lucerne Treatment of elderly multiple myeloma patients Federica Cavallo, MD, PhD Federica Cavallo, MD, PhD Division
More informationTreatment Strategies for Transplant-ineligible NDMM Patients
1 Treatment Strategies for Transplant-ineligible NDMM Patients Thierry Facon, MD Professor of Hematology Service des Maladies du Sang University of Lille Lille, France Multiple Myeloma affects primarily
More informationManagement of Multiple Myeloma: The Changing Paradigm
Management of Multiple Myeloma: The Changing Paradigm High-Dose Chemotherapy and Stem Cell Transplantation Todd Zimmerman, MD University of Chicago Medical Center Case Presentation R.M. is a 64 year old
More informationChoosing upfront and salvage therapy for myeloma in the ASEAN context
Choosing upfront and salvage therapy for myeloma in the ASEAN context Daryl Tan Consultant Department of Haematology Singapore General Hospital Adjunct Assistant Professor Duke-NUS Graduate Medical School
More informationRisk stratification in the older patient; what are our priorities?
Risk stratification in the older patient; what are our priorities? Sonja Zweegman MD PhD Amsterdam The Netherlands Negative impact of age on survival Meta-analysis of European trials (MP vs MPT, VMP vs
More informationGetting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions
Getting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions Friday, December 8, 2017 Atlanta, Georgia Friday Satellite Symposium preceding the 59th ASH Annual Meeting &
More informationConsolidation after Autologous Stem Cell Transplantion
Consolidation after Autologous Stem Cell Transplantion Joan Bladé Laura Rosiñol Department of Hematology Hospital Clínic de Barcelona Berlin, September 11 th 2011 Autologous Stem Cell Transplant in Younger
More informationPost Transplant Maintenance- for everyone? Disclosures
Post Transplant Maintenance- for everyone? NO Because of limited survival data, not all patients require maintenance April 2012 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Joseph Mikhael,
More informationTo Maintain or Not to Maintain? Lymphoma and Myeloma 2015 Waldorf Astoria Hotel, New York
To Maintain or Not to Maintain? Lymphoma and Myeloma 2015 Waldorf Astoria Hotel, New York Sundar Jagannath Director, Multiple Myeloma Program Tisch Cancer Institute Mount Sinai Medical Center Maintenance
More informationCREDIT DESIGNATION STATEMENT
CME Information LEARNING OBJECTIVES Integrate emerging research information on the use of proteasome inhibitors and immunomodulatory agents to individualize induction treatment recommendations and maintenance
More informationMAINTENANCE AND CONTINUOUS THERAPY OF MYELOMA. Myeloma Day 11/18/2017 Aric Hall, MD Assistant Professor UW School of Medicine & Public Health
MAINTENANCE AND CONTINUOUS THERAPY OF MYELOMA Myeloma Day 11/18/2017 Aric Hall, MD Assistant Professor UW School of Medicine & Public Health Disclosures I have no significant conflicts of interest to disclose.
More informationMultiple Myeloma: Diagnosis and Primary Treatment
Multiple Myeloma: Diagnosis and Primary Treatment George Somlo, MD City of Hope Comprehensive Cancer Center NCCN.org For Clinicians NCCN.org/patients For Patients Educational Objectives Discuss considerations
More informationCurrent Management of Multiple Myeloma. December 2012 Kevin Song MD FRCPC Leukemia/BMT Program of B.C.
Current Management of Multiple Myeloma December 2012 Kevin Song MD FRCPC Leukemia/BMT Program of B.C. Disclosures Honoraria Speaker Celgene, Janssen, Novartis Celgene, Janssen Research Support Celgene
More informationNovel treatment strategies for multiple myeloma: a focus on oral proteasome inhibitors
Novel treatment strategies for multiple myeloma: a focus on oral proteasome inhibitors Antonio Palumbo M.D. Takeda Pharmaceuticals International AG Introduction Multiple genetically-distinct subclones
More informationApproach to the Treatment of Newly Diagnosed Multiple Myeloma. S. Vincent Rajkumar Professor of Medicine Mayo Clinic
Approach to the Treatment of Newly Diagnosed Multiple Myeloma S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of
More informationAntibodies are a standard part of first relapse management in multiple myeloma (MM): Yes
Antibodies are a standard part of first relapse management in multiple myeloma (MM): Yes Ajay Nooka, MD MPH FACP Assistant Professor, Division of Bone Marrow Transplant Winship Cancer Institute, Emory
More informationWhat New in Hematopoietic Stem Cell Transplantation? Joseph M. Tuscano, M.D. UCD Cancer Center
What New in Hematopoietic Stem Cell Transplantation? Joseph M. Tuscano, M.D. UCD Cancer Center 1 JOSEPH TUSCNO, MD WHAT S NEW IN HEMATOPOEITIC STEM CELL TRANSPLANTATION? RELEVANT FINANCIAL RELATIONSHIPS
More informationIs Transplant a Necessity or a Choice: Focus on the necessity for CR and MRD
Is Transplant a Necessity or a Choice: Focus on the necessity for CR and MRD Ajai Chari, MD Associate Professor of Medicine Director of Clinical Research Multiple Myeloma Program Mount Sinai Medical Center
More informationRelapsed Myeloma Sequencing Treatments
Relapsed Myeloma Sequencing Treatments Noopur Raje, MD Director, Center for Multiple Myeloma MGH Cancer Center Professor of Medicine Harvard Medical School Disclosures Consultant /Advisory Board: Celgene,
More informationIl trattamento del Mieloma su stratificazione di rischio: è oggi possibile?
Il trattamento del Mieloma su stratificazione di rischio: è oggi possibile? Francesca Gay, MD Divisione Ematologia 1 AO Città della Salute e della Scienza, Torino, Italy Focus sul MM 2014 Cagliari, 30-31
More informationHow to Integrate the New Drugs into the Management of Multiple Myeloma
How to Integrate the New Drugs into the Management of Multiple Myeloma Carol Ann Huff, MD The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins NCCN.org For Clinicians NCCN.org/patients For Patients
More informationNew Treatment Paradigms in Transplant-Eligible Myeloma Patients
New Treatment Paradigms in Transplant-Eligible Myeloma Patients Michele Cavo Seràgnoli Institute of Hematology, Bologna University School of Medicine, Italy Turkey, March 1 st 2013 NEW TREATMENT PARADıGM
More informationMyeloma update ASH 2014
Myeloma update ASH 2014 Updates in Newly Diagnosed Multiple Myeloma FIRST: effect of age on lenalidomide/dexamethasone vs MPT in transplantation-ineligible pts Phase III: MPT-T vs MPR-R in transplantation-ineligible
More informationMultiple Myeloma in 2016 Progress and Challenges DONNA E. REECE, M.D. PRINCESS MARGARET CANCER CENTRE 01 APRIL 2016
Multiple Myeloma in 2016 Progress and Challenges DONNA E. REECE, M.D. PRINCESS MARGARET CANCER CENTRE 01 APRIL 2016 Key Features of Myeloma Biology Myeloma is not one disease 1 At least 7 subtypes based
More informationAutologous Stem Cell Transplanation as First line Treatment? (Against) Joan Bladé Berlin, September 9 th, 2011
Autologous Stem Cell Transplanation as First line Treatment? (Against) Joan Bladé Berlin, September 9 th, 2011 Significant impact of ASCT before the availability of novel agents? Randomized trials: Single
More informationManagement of Multiple
Management of Multiple Myeloma in the Elderly Xavier Leleu Service des Maladies du Sang Hôpital Huriez, CHRU, Lille, France INSERM U837, équipe 3 IRCL, CHRU, Lille, France IMPRT Institut de Médecine Prédictive
More informationBest of ASH 2017 DR. BRIAN DURIE. Brian GM Durie, MD Thursday, January 11, 2018
Best of ASH 2017 DR. BRIAN DURIE Brian GM Durie, MD Thursday, January 11, 2018 1 ASH Overview 2017 Total myeloma abstracts: 981 Important/Interesting: oral ~40 posters ~60 100 2 Which abstracts impact
More informationNovel Therapies for the Treatment of Newly Diagnosed Multiple Myeloma
Novel Therapies for the Treatment of Newly Diagnosed Shaji K. Kumar, MD Professor of Medicine Mayo Clinic College of Medicine Consultant, Division of Hematology Medical Director, Cancer Clinical Research
More informationInduction Therapy & Stem Cell Transplantation for Myeloma
Induction Therapy & Stem Cell Transplantation for Myeloma William Bensinger, MD Professor of Medicine, Division of Oncology University of Washington School of Medicine Director, Autologous Stem Cell Transplant
More informationManagement of Multiple Myeloma
Management of Multiple Myeloma Damian J. Green, MD Fred Hutchinson Cancer Research Center/ Seattle Cancer Care Alliance New Treatment Options Have Improved OS in MM Kumar SK, et al. Blood. 2008;111:2516-2520.
More informationIMiDs (Immunomodulatory drugs) and Multiple Myeloma
www.comtecmed.com/comy comy@comtecmed.com IMiDs (Immunomodulatory drugs) and Multiple Myeloma Xavier Leleu Service des Maladies du Sang Hôpital Huriez, CHRU, Lille, France www.comtecmed.com/comy comy@comtecmed.com
More informationMultiple Myeloma: ASH 2008
Multiple Myeloma: ASH 2008 Steven Coutre, M.D. Associate Professor of Medicine Division of Hematology Stanford University School of Medicine About These Slides These slides accompany CCO s comprehensive
More informationTreatment of elderly patients with multiple myeloma
Treatment of elderly patients with multiple myeloma Mario Boccadoro DIVISIONE UNIVERSITARIA DI EMATOLOGIA AZIENDA OSPEDALIERA SAN GIOVANNI TORINO, ITALY Improved survival in multiple myeloma and the impact
More informationHighlights in multiple myeloma
3 CONGRESS HIGHLIGHTS Highlights in multiple myeloma P. Vlummens, MD SUMMARY Multiple myeloma (MM) remains a devastating disease, even in the era of novel agents. As such, the search for new treatment
More information2015 Updates in Multiple Myeloma
2015 Updates in Multiple Myeloma Siddhartha Ganguly, MD, FACP Professor of Medicine Director, Lymphoma and Myeloma Blood and Marrow Transplantation Program The University of Kansas Medical Center 1 Earliest
More informationMultiple Myeloma Brian Berryman, M.D. March 8 th, 2014
Multiple Myeloma 2014 Brian Berryman, M.D. March 8 th, 2014 Kyle, R. A. et al. Blood 2008;111:2962-2972 Updates in Multiple Myeloma CCO Independent Conference Coverage of the 2013 Annual Meeting of
More informationMULTIPLE MYELOMA. The clonoseq Assay can predict progressionfree survival in myeloma patients
MULTIPLE MYELOMA With current therapies, complete response (CR) is reached in 3-5% of multiple myeloma () patients. 1 However, most of these patients will experience relapse due to the persistence of residual
More informationStudy Objectives: GMMG MM5
Study Objectives: GMMG MM5 1.) Demonstration of non-inferiority of VCD induction therapy compared to PAd induction therapy with respect to response rate (very good partial remission or better; response
More informationMultiple Myeloma Updates 2007
Multiple Myeloma Updates 2007 Brian Berryman, M.D. Multiple Myeloma Updates 2007 Goals for today: Understand the staging systems for myeloma Understand prognostic factors in myeloma Review updates from
More informationMinimal residual disease. Bruno Paiva University of Navarra, Spain
Minimal residual disease Bruno Paiva University of Navarra, Spain 1st World Congress on Controversies in Multiple Myeloma. Bangkok, Thailand. May 11-13 214 Oprozomib (ONX 912) Phase I/II Autologous bone
More informationHow to treat a newly diagnosed young patient with multiple myeloma
How to treat a newly diagnosed young patient with multiple myeloma J.F. San Miguel University of Salamanca, Spain Department of Haematology University of Salamanca Cancer Research Centre Disclosures for
More informationAdvances in the Management of Myeloma Parameswaran Hari, MD
Advances in the Management of Myeloma Parameswaran Hari, MD Medical College of Wisconsin Milwaukee, WI What is the standard? Induction/Transplant/Maintenance UPDATED OS DATA from CALGB 100104 & IFM 2005-02
More informationIn-depth look at specific data-sets; which ones meet requirements? Individual data owners /cooperative groups
In-depth look at specific data-sets; which ones meet requirements? Individual data owners /cooperative groups Minimal Residual Disease (MRD) by Multiparameter Flow Cytometry (MFC) in transplant eligible
More informationClinical Decision Making in Multiple Myeloma for the Transplant-Eligible Patient Upfront Transplant Versus Maintenance Therapy
Clinical Decision Making in Multiple Myeloma for the Transplant-Eligible Patient Upfront Transplant Versus Maintenance Therapy Noa Biran, MD, and David Vesole, MD, PhD Introduction High dose chemotherapy
More informationLiving Well with Myeloma Teleconference Series Thursday, March 24 th :00 PM Pacific/5:00 PM Mountain 6:00 PM Central/7:00 PM Eastern
Living Well with Myeloma Teleconference Series Thursday, March 24 th 216 4: PM Pacific/5: PM Mountain 6: PM Central/7: PM Eastern Speakers Dr. Brian Durie, IMF Chairman Cedars Sinai Samuel Oschin Cancer
More informationRole of Stem Cell Transplantation in Multiple Myeloma: The Changing Landscape
Role of Stem Cell Transplantation in Multiple Myeloma: The Changing Landscape Simrit Parmar, MD MDACC Houston, TX, USA Why Transplant in the Era of Novel Therapy? Safe (TRM
More informationDaratumumab: Mechanism of Action
Phase 3 Randomized Controlled Study of Daratumumab, Bortezomib and Dexamethasone (D) vs Bortezomib and Dexamethasone () in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): CASTOR* Antonio
More informationUpfront Therapy for Myeloma Tailoring Therapy across the Disease Spectrum
Upfront Therapy for Myeloma Tailoring Therapy across the Disease Spectrum S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic
More informationSTUDY DESIGN. VMP 6-week cycles, total of 9 cycles. Figure 2. Alcyone study design. Countries housing study sites are shaded in gold.
TPS8608 A Randomized Open-label Study of Bortezomib, Melphalan, And Prednisone (VMP) Versus Daratumumab () Plus VMP in Patients With Previously Untreated Multiple Myeloma (MM) Who Are Ineligible for High-dose
More informationDebate: Is transplant a necessity or a choice? Focus on the necessity for CR and MRD. Answer: NO
Debate: Is transplant a necessity or a choice? Focus on the necessity for CR and MRD. Answer: NO Tomer M. Mark Department of Medicine, Division of Hematology / Oncology Weill-Cornell Medical College /
More informationIntegration of Novel Therapy Into Myeloma Management
Updates on Diagnostic Criteria and Management of Multiple Myeloma Kenneth C. Anderson, MD Dana-Farber Cancer Institute Integration of Novel Therapy Into Myeloma Management Bortezomib, lenalidomide, thalidomide,
More informationModule 3: Multiple Myeloma Induction and Transplant Strategies Treatment Planning
Module 3: Multiple Myeloma Induction and Transplant Strategies Treatment Planning Challenge Question: Role of Autologous Stem Cell Transplant Which of the following is true about eligibility for high-dose
More informationMULTIPLE MYELOMA. The clonoseq Assay can predict progressionfree survival in myeloma patients
MULTIPLE MYELOMA With current therapies, complete response (CR) is reached in 3-5% of multiple myeloma () patients. 1 However, most of these patients will experience relapse due to the persistence of residual
More informationTransplant in MM patients: Early versus late. Mario Boccadoro. Barcelona
Transplant in MM patients: Early versus late Barcelona 8-9-2012 Mario Boccadoro DIVISIONE UNIVERSITARIA DI EMATOLOGIA AZIENDA OSPEDALIERA SAN GIOVANNI TORINO, ITALY Transplant in MM patients: Early versus
More informationGetting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions
Getting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions Friday, December 8, 2017 Atlanta, Georgia Friday Satellite Symposium preceding the 59th ASH Annual Meeting &
More informationMichel Delforge Belgium. New treatment options for multiple myeloma
Michel Delforge Belgium New treatment options for multiple myeloma Progress in the treatment of MM over the past 40 years 1962 Prednisone + melphalan 1990s Supportive care 1999 First report on thalidomide
More informationIs Myeloma Curable in 2012?
Is Myeloma Curable in 2012? YES Cure is living long enough to die of another cause April 2012 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Joseph Mikhael, MD, MEd, FRCPC Staff Hematologist,
More informationUpdates in Multiple Myeloma: 12 months in 10 minutes
Updates in Multiple Myeloma: 12 months in 10 minutes Aaron Rosenberg MD, MS Assistant Prof. Medicine UC Davis Comprehensive Cancer Center Division of Hematology and Oncology Outline Standard of care for
More informationOptimal maintenance and consolidation therapy for multiple myeloma in actual clinical practice
REVIEW Korean J Intern Med 2016;31:809-819 Optimal maintenance and consolidation therapy for multiple myeloma in actual clinical practice Ho Sup Lee 1 and Chang-Ki Min 2 1 Department of Internal Medicine,
More informationLONDON CANCER NEWS DRUGS GROUP RAPID REVIEW
LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW Bortezomib as first line induction prior to melphalan and autologous stem cell transplantation (ASCT) in untreated symptomatic multiple myeloma patients suitable
More informationNovel Treatment Advances and Approaches in Management of Relapsed/Refractory Multiple Myeloma
Novel Treatment Advances and Approaches in Management of Relapsed/Refractory Multiple Myeloma Ravi Vij, MD MBA Professor of Medicine Washington University School of Medicine Section of Stem Cell Transplant
More informationRole of stem cell transplant and maintenance therapy in plasma cell disorders
MYELOMA Role of stem cell transplant and maintenance therapy in plasma cell disorders Philip L. McCarthy 1 and Sarah A. Holstein 2 1 Department of Medicine, Blood and Marrow Transplant Program, Roswell
More information